USANA Health Sciences USNA Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation at other companies
Other financials
Where this comes from
Reported directly by USANA Health Sciences in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The official record: USANA Health Sciences’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about USANA Health Sciences's cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is USANA Health Sciences's cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation?
- USANA Health Sciences (USNA) reported cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation of $4.42M in Q1 2026.
- How has USANA Health Sciences's cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation changed year-over-year?
- USANA Health Sciences's cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation increased by 306.3% year-over-year, from -$2.14M to $4.42M.
- What is the long-term trend for USANA Health Sciences's cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation?
- Over 2 years (2022 to 2024), USANA Health Sciences's cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation has grown at a 76.6% compound annual growth rate (CAGR), from $47.67M to -$148.74M.
- What does cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation mean?
- Represents the net change in the total cash position, including restricted cash, over a specific reporting period after accounting for operating, investing, and financing activities. It is the primary indicator of the company's overall liquidity health and cash generation capability.